Plasma multi-omics prediction of left ventricular remodeling and major cardiac events after STEMI

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Investigators prospectively collected serial blood samples and performed echocardiography in adults with a first ST-segment elevation myocardial infarction (STEMI) treated by primary PCI, then followed patients for six months to identify those who developed left ventricular adverse remodeling (LVAR). Cases with LVAR were matched to non-remodeling controls in a nested case-control design and analyzed using multi-omics methods including exosome proteomics, metabolomics, transcriptomics, lipidomics and immunomics. The project integrates these data to identify plasma biomarker signatures and molecular pathways associated with LVAR and subsequent major adverse cardiovascular events (MACE). Findings aim to generate prognostic signatures that could be validated in future cohorts.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥18 years and ≤80 years.
2. Definite diagnosis of STEMI according to ESC/ACC guidelines:

   * Chest pain lasting \>30 minutes, and
   * ST-segment elevation in at least two contiguous leads: ≥0.2 mV in leads V2-V3 (≥0.2 mV for men, ≥0.15 mV for women) or ≥0.1 mV in other leads, or new-onset left bundle branch block.
3. Reperfusion therapy: Symptom onset to first medical contact ≤12 hours, and successful primary PCI (culprit vessel opened, post-procedure TIMI flow grade 3).
4. First STEMI (no prior history of myocardial infarction).
5. Left ventricular ejection fraction (by echocardiography within 24-48 hours after admission) ≥35%.
6. Informed consent: Signed informed consent obtained, with willingness to undergo serial blood sampling and echocardiographic follow-up.

Exclusion Criteria:

1. Non-atherosclerotic MI: coronary embolism, spasm, aortic dissection, myocarditis, Takotsubo.
2. Severe comorbidities:

   * Prior HF (NYHA ≥II);
   * Severe CKD (eGFR \<30 mL/min/1.73m² or dialysis);
   * Severe liver disease (Child-Pugh B/C);
   * Active malignancy (life expectancy \<1 year);
   * Severe hematologic disorders (thrombocytopenia, coagulopathy, active bleeding).
3. Fibrinolysis-followed-by-PCI.
4. Primary PCI complications:

   * No-reflow/slow-flow (final TIMI \<2);
   * Cardiogenic shock or mechanical complication within 7 days;
   * In-hospital repeat revascularization.
5. Inability to complete 6-month follow-up.
6. Factors affecting blood sampling/exosome/immune/proteome assays:

   * Blood transfusion within 1 month;
   * Known hemolytic disorder;
   * Inadequate venous access.
7. Pregnancy or lactation.

Where it's running

• Beijing Anzhen Hospital, Capital Medical University.
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Principal investigator: Xu Wang, Dr. — Beijing Anzhen hospital, Capital Mediacl University.
• Study coordinator: Xu Wang, Dr.
• Email: huaianwangxu@126.com
• Phone: +8617810688257

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Is geographic mismatch linked to short-term major heart problems after long drug-eluting stent placement?

  This study checks whether geographic mismatch can predict short-term major adverse cardiovascular events after a long drug-eluting stent is placed in the coronary arteries.

  Recruiting Sohag University · Sohag · NCT07890181

• Cold-region exposure and heart remodeling after PCI

  This study tests whether long-term cold exposure before PCI is linked to worse heart remodeling and outcomes in people with coronary artery disease.

  Recruiting Chinese PLA General Hospital · Beijing, Please Select An Option Below · NCT07773870

• Assessing the Systolic Rise Time's ability to predict limb and cardiovascular events in severe peripheral artery disease

  This study is testing if a specific measurement from the foot can help predict serious problems with limbs and heart health in people with severe peripheral artery disease.

  Recruiting Centre Hospitalier Universitaire, Amiens · Amiens · NCT06318767

• Using CCTA to improve management of stable chest pain

  This study is testing if using a special heart scan called CCTA can help doctors better manage stable chest pain and reduce serious heart problems for patients suspected of having blocked arteries.

  Recruiting at 4 sites Tianjin Chest Hospital · Beijing, Beijing Municipality and 3 other locations · NCT04691037

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.